Literature DB >> 24034181

A systematic review of sevoflurane and isoflurane minimum alveolar concentration in domestic cats.

Mike R Shaughnessy1, Erik H Hofmeister.   

Abstract

OBJECTIVE: The purpose of this systematic review is to summarize the results of studies which have determined the minimum alveolar concentration (MAC) of isoflurane and sevoflurane in domestic cats. STUDY
DESIGN: Systematic review. ANIMALS: Cats. METHODS USED: A comprehensive search of research literature was performed without language restriction. The search utilized the Pubmed, Google Scholar, and CAB Abstracts electronic databases using a combination of free text terms 'Minimum alveolar concentration', 'sevoflurane', 'isoflurane', 'anesthetic', 'cat', 'cats' or 'feline'. The search was conducted from November 2010 to June 2012.
RESULTS: The MAC for isoflurane ranged from 1.20 ± 0.13% to 2.22 ± 0.35% and the MAC for sevoflurane ranged from 2.5 ± 0.2% to 3.95 ± 0.33%. The average MAC for isoflurane was 1.71 ± 0.07% and for sevoflurane was 3.08 ± 0.4%. CONCLUSIONS & CLINICAL RELEVANCE: The average MAC for isoflurane was 1.71 ± 0.07% and for sevoflurane was 3.08 ± 0.4%. Methodology differed among studies, and particular attention should be paid in the future to appropriate reporting of methods to allow sound conclusions to be made from the results.
© 2013 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesia and Analgesia.

Entities:  

Keywords:  cats; isoflurane; minimum alveolar concentration; sevoflurane; stimulation

Mesh:

Substances:

Year:  2013        PMID: 24034181     DOI: 10.1111/vaa.12083

Source DB:  PubMed          Journal:  Vet Anaesth Analg        ISSN: 1467-2987            Impact factor:   1.648


  1 in total

1.  Lidocaine, dexmedetomidine and their combination reduce isoflurane minimum alveolar concentration in dogs.

Authors:  Carlos M Acevedo-Arcique; José A Ibancovichi; Julio R Chavez; Eduardo Gutierrez-Blanco; Rafael Moran-Muñoz; José M Victoria-Mora; Francisco Tendillo-Cortijo; Martín Santos-González; Pedro Sanchez-Aparicio
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.